VKTX - Intercept And The Clinical Reality Of Treating NASH Fibrosis
Intercept's data in NASH fibrosis get a muted reception
Intercept Pharmaceuticals (ICPT) last week announced data from its pivotal REGENERATE PhIII trial evaluating lead drug obeticholic acid ('OCA'), currently marketed as OCALIVA, in patients with liver fibrosis due to NASH. OCA has received breakthrough therapy designation in this indication and the drug benefits from IP protection through 2033 per company estimates.
While the stock spiked some 30% at the open on Feb. 19, this surge in share price was short-lived:
ICPT 5-day chart showing the surge on Feb. 19 following announcement of